Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Holding JAZZ?
Track your performance easily
JAZZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.06 - $134.17
Previous Close$127.12
Volume607.36K
Average Volume (3M)656.27K
Market Cap
$7.68B
Enterprise Value$11.65B
Total Cash (Recent Filing)$2.22B
Total Debt (Recent Filing)$6.18B
Price to Earnings (P/E)18.3
Beta0.66
Next Earnings
Mar 04, 2025EPS Estimate
$5.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.94
Shares Outstanding60,454,592
10 Day Avg. Volume701,067
30 Day Avg. Volume656,270
Standard Deviation0.09
R-Squared0.12
Alpha-0.00539
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)1.87
Price to Cash Flow (P/CF)4.70
P/FCF Ratio4.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.92
Enterprise Value/Gross Profit3.43
Enterprise Value/Ebitda12.63
Forecast
1Y Price Target
$181.93Price Target Upside42.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Jazz Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe 3Q24 earnings per share (EPS) of $6.61 exceeded expectations, driven by higher revenues and reduced operational expenses.
Product DevelopmentThe ongoing Phase 3 zani trial in 1L gastric cancer is seen as a key stock multiple re-rating catalyst, potentially contributing over $1 billion in peak sales.
Product GrowthXywav for narcolepsy showed impressive growth of 10%, following a 5-6% growth earlier, indicating strong market performance.
Bears Say
Competitive ChallengesOutlook for Xywav in narcolepsy and IH faces challenges with entry of generics and other competitors.
Market GrowthThe narcolepsy market is more mature and has seen less growth overall due to competition from authorized generics and branded fixed dose products.
Oncology SegmentThe oncology sales guidance range was lowered, suggesting potential challenges in this segment.
---
Ownership Overview
3.27% Insiders
26.36% Mutual Funds
6.43% Other Institutional Investors
36.68% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $99.06 and its highest was $134.17 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 112 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $6.61 earnings per share for the quarter, beating the consensus estimate of $5.498 by $1.112.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is $5.92.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,454,594 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.61 in its last earnings report, beating expectations of $5.498. Following the earnings report the stock price went up 6.75%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 147M.
---
Jazz Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$181.93 (42.46% Upside)
$181.93 (42.46% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 396.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.75%
12-Months-Change
Fundamentals
Return on Equity
12.09%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q3 2024
0:00 / 0:00
---
JAZZ Stock 12 Month Forecast
Average Price Target
$181.93
▲(42.46% Upside)
Technical Analysis
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
18/25 ratings generated profit
1 Year Average Return
+7.18%
reiterated a buy rating 6 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +7.18% per trade.
---